14.45 – 15.25 Marilyn Bui - Embracing Digital and Computational Pathology: A Calling for Pathologists as Leaders in Precision Medicine
Digital health data ecosystem is emerging as an important pillar to the delivery of precision medicine. Digital pathology enabled by whole slide imaging (WSI) and computational pathology /artificial intelligence is an essential component of digital health. Pathologists are at the forefront of delivery quality care to patients by providing accurate diagnostic, prognostic and predictive information. FDA approval of WSI for primary diagnosis and quantitative image analysis of immunohisochemical breast biomarkers demonstrate that digital pathology is a proven and essential technology. Rapid progress on computational pathology and artificial intelligence presents boundless opportunity in augment pathologists’ ability to lead better delivery of precision medicine. This presentation will address the challenges and opportunities as well as resources, guides and guidelines in this area. It is also a snap shot of DPA’s recent accomplishments on advocacy, education and collaboration to influence removing regulatory barrier, shaping standards, and promoting best practices, and the use of the technology to ultimate benefit scientific discovery and patient care.
CV Marilyn M. Bui, MD, PhD is a Professor of Pathology, Scientific Director of Analytic Microscopy Core, President of Medical Staff, and Director of the Cytopathology Fellowship at Moffitt Cancer Center, a top ranked comprehensive cancer center in America. Her expertise is in bone and soft tissue pathology, cytopathology, biomarker testing and digital pathology. In digital pathology, she is the President of the Digital Pathology Association, Vice Chair of the College of American Pathologists (CAP) Digital Pathology Committee, and an editorial board member of Journal of Pathology Informatics. She also chaired the CAP Quantitative Image Analysis (QIA) of HER2 Immunohistochemistry (IHC) for Breast Cancer expert panel which developed an evidence-based guideline to improve accuracy and reproducibility of the interpretation of HER2 IHC by QIA. She has published over 185 peer-reviewed articles, 20 book chapters and 3 books. She has received national and institutional awards in research, education and service. Digital pathology has significantly enhanced Dr. Bui’s ability in delivering quality patient care through cancer diagnosis, research and education. Dr. Bui is recognized by The Pathologist magazine as one of its inaugural Top 100 Power List, which celebrates the exceptional achievements of those who have really had an impact on the field and highlights the truly groundbreaking work of laboratory medicine and its intrinsic role in patient care and the molecular revolution, and in 2018 again Dr. Bui was named to The Pathologist Power List.